Method of ameliorating uremia
US-2017224652-A1 · Aug 10, 2017 · US
Treatment of pulmonary arterial hypertension with mesenchymal stem cells
US10071123B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10071123-B2 |
| Application number | US-201314418553-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 30, 2013 |
| Priority date | Aug 1, 2012 |
| Publication date | Sep 11, 2018 |
| Grant date | Sep 11, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition comprising treprostinil or a pharmaceutically acceptable salt or ester thereof, a composition comprising a mesenchymal stem cell (MSC) or a part of a culture medium that has been in contact with the MSC and contains one or more components of the MSC, and a pharmaceutically acceptable carrier, wherein the MSC has been pre-treated ex vivo with treprostinil or a pharmaceutically acceptable salt or ester thereof during expansion of the MSC. 2. The composition of claim 1 , further comprising an endothelial progenitor cell (EPC). 3. The composition of claim 1 , wherein the pharmaceutical composition does not comprise an endothelial progenitor cell.
Assignees
Inventors
Classifications
Antihypertensives · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Drugs for disorders of the cardiovascular system · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10071123B2 cover?
- The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal s…
- Who is the assignee on this patent?
- United Therapeutics Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5585. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).